Overview

* Unicycive reports Q3 net loss of $6.0 mln, up from $4.1 mln year-over-year

* Company plans to resubmit NDA for OLC by year-end after FDA discussions

* Unicycive ends Q3 with $42.7 mln cash, runway into 2027

Outlook

* Unicycive plans to resubmit NDA for OLC by year-end

* Company expects cash runway into 2027

* Unicycive anticipates potential OLC launch next year

Result Drivers

* NDA RESUBMISSION - Co plans to resubmit NDA for OLC by year-end after positive FDA discussions and vendor inspection

* PILL BURDEN REDUCTION - OLC significantly reduced pill burden compared to current phosphate binders, as presented at ASN

* CASH POSITION - Ended Q3 with $42.7 mln cash, providing runway into 2027

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$6.01

Income mln

Q3 -$7.34

Income mln

from

Operatio

ns

Q3 $7.34

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Unicycive Therapeutics Inc ( UNCY ) is $45.00, about 89.4% above its November 11 closing price of $4.79

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)